Dhan Chand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dhan Chand has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Kah Teong Soh
Agenus, Lexington, USA
71 shared publications - Tyler J. Curiel
South Texas Medical Scientist Training Program, University of Texas Health, San Antonio, USA
71 shared publications - Alvaro Sebastian-Yague
MiNK Therapeutics, Lexington, Massachusetts
70 shared publications - Bishnu Joshi
Agenus, Lexington, Massachusetts
70 shared publications - Jennifer S. Buell
Agenus Inc, Lexington, USA
70 shared publications - Justin G. Keith
Agenus, Lexington, Massachusetts
70 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
C-800-01 SAP 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Statistical analysis plan to support the main manuscript.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessC-800-01 SAP 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Statistical analysis plan to support the main manuscript.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
C-800-01 Protocol 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Clinical trial protocol to support the main manuscript.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessC-800-01 Protocol 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Clinical trial protocol to support the main manuscript.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025. an = 121 patients with percent change from baseline in tumor measurement. bResponse data for this patient were corrected because of a documented database error identified after database lock; correction reflects validated source data.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025. an = 121 patients with percent change from baseline in tumor measurement. bResponse data for this patient were corrected because of a documented database error identified after database lock; correction reflects validated source data.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) PFS and (B) OS in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) PFS and (B) OS in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in patients with MSS mCRC NLM previously exposed to available late-line therapiesa who received either dose of BOT + BAL. Data cutoff: December 13, 2025. aReceived ≥1 prior regimen of regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib. This was an exploratory, post hoc subgroup analysis.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in patients with MSS mCRC NLM previously exposed to available late-line therapiesa who received either dose of BOT + BAL. Data cutoff: December 13, 2025. aReceived ≥1 prior regimen of regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib. This was an exploratory, post hoc subgroup analysis.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Demographics and baseline disease characteristics of all patients with MSS mCRC NLM (N = 123).
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Demographics and baseline disease characteristics of all patients with MSS mCRC NLM (N = 123).
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Safety overview, including the most common treatment-related imAE and TRAE (occurred in ≥10% of patients with MSS mCRC NLM; N = 123).
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Safety overview, including the most common treatment-related imAE and TRAE (occurred in ≥10% of patients with MSS mCRC NLM; N = 123).
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Efficacy overview in all patients with MSS mCRC NLM (N = 123).
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Efficacy overview in all patients with MSS mCRC NLM (N = 123).
- Open Access
- 28 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4817-4828
Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Purpose: Microsatellite-stable metastatic colorectal cancer (MSS mCRC) has limited treatment options and responds poorly to conventional immunotherapy. We report extended follow-up results from a fully enrolled, phase Ib cohort evaluating botensilimab [BOT; Fc-enhanced anti–cytotoxic T-lymphocyte–associated protein 4 (CTLA-4)] plus balstilimab [BAL; anti–programmed cell death protein 1 (PD-1)] in patients with MSS mCRC and no active liver metastases (NLM). Patients and Methods: Patients received BOT 1 or 2 mg/kg every 6 weeks plus BAL 3 mg/kg every 2 weeks up to 2 years or until progression or unacceptable toxicity. The primary objective was safety/tolerability. Efficacy endpoints included objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS); overall survival (OS) was exploratory. Patients with prior regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib (“late-line exposed”) were analyzed post hoc. Results: As of December 13, 2025, 123 patients were treated [median follow-up, 20.2 months (range, 0.7–62.3)]. The median prior lines was 3 (range, 1–10; 67% had ≥3 prior lines). The most common treatment-related adverse events were diarrhea (39%; grade ≥3, 8%) and fatigue (37%; grade ≥3, 2%). The ORR was 21% [95% confidence interval (CI), 14–29]. The median DOR was not reached (NR; 95% CI, 7.3–NR), the median PFS was 4.0 months (95% CI, 2.8–4.1), and the median OS was 21.2 months [95% CI, 16.2–23.8; 36-month OS, 33% (95% CI, 24–43)]. Efficacy was consistent in late line–exposed patients [n = 37; ORR, 22% (95% CI, 10–38); median OS, 16.2 months (95% CI, 9.7–31.3)]. Conclusions: BOT + BAL demonstrated durable responses, long-term survival, and manageable safety in previously treated MSS mCRC NLM, including in late line–exposed patients. These results support further evaluation.
- 28 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4817-4828
Open AccessExtended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Purpose: Microsatellite-stable metastatic colorectal cancer (MSS mCRC) has limited treatment options and responds poorly to conventional immunotherapy. We report extended follow-up results from a fully enrolled, phase Ib cohort evaluating botensilimab [BOT; Fc-enhanced anti–cytotoxic T-lymphocyte–associated protein 4 (CTLA-4)] plus balstilimab [BAL; anti–programmed cell death protein 1 (PD-1)] in patients with MSS mCRC and no active liver metastases (NLM). Patients and Methods: Patients received BOT 1 or 2 mg/kg every 6 weeks plus BAL 3 mg/kg every 2 weeks up to 2 years or until progression or unacceptable toxicity. The primary objective was safety/tolerability. Efficacy endpoints included objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS); overall survival (OS) was exploratory. Patients with prior regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib (“late-line exposed”) were analyzed post hoc. Results: As of December 13, 2025, 123 patients were treated [median follow-up, 20.2 months (range, 0.7–62.3)]. The median prior lines was 3 (range, 1–10; 67% had ≥3 prior lines). The most common treatment-related adverse events were diarrhea (39%; grade ≥3, 8%) and fatigue (37%; grade ≥3, 2%). The ORR was 21% [95% confidence interval (CI), 14–29]. The median DOR was not reached (NR; 95% CI, 7.3–NR), the median PFS was 4.0 months (95% CI, 2.8–4.1), and the median OS was 21.2 months [95% CI, 16.2–23.8; 36-month OS, 33% (95% CI, 24–43)]. Efficacy was consistent in late line–exposed patients [n = 37; ORR, 22% (95% CI, 10–38); median OS, 16.2 months (95% CI, 9.7–31.3)]. Conclusions: BOT + BAL demonstrated durable responses, long-term survival, and manageable safety in previously treated MSS mCRC NLM, including in late line–exposed patients. These results support further evaluation.